Can we harness the immune system to fight aCSCC?

Identifying the potential for immune engagement in aCSCC

Learn more about critical pathways in immune response

Innovations in immunotherapy are emerging

View in Browser

Advancing our understanding of the immune response may shed light on key pathways

Dear [Dr] [Doe],

Addressing the needs of patients with aCSCC begins with taking a broader look at the tumor microenvironment and its critical defense mechanisms.

How can we expand potential immune engagement in aCSCC?

By leveraging the potential of the adaptive and innate immune responses, can we interfere with tumor cell evasion and help patients with aCSCC?¹

Explore the role of the PD-L2 pathway and how it may influence tolerability.²

Learn more about aCSCC:

aCSCC=advanced cutaneous squamous cell carcinoma (locally advanced and metastatic disease); imAE=immune-mediated adverse event; NK=natural killer; PD-1=programmed cell-death protein 1; PD-L1=programmed death-ligand 1; PD-L2=programmed death-ligand 2.

References: 1. Wang R, Lan C, Benlagha K, et al. The interaction of innate immune and adaptive immune system. MedComm (2020). 2024;5(10):e714. doi:10.1002/mco2.714 2. Chen RY, Zhu Y, Shen YY, et al. The role of PD-1 signaling in health and immune-related diseases. Front Immunol. 2023;14:1163633. doi:10.3389/fimmu.2023.1163633

Sun Pharmaceutical Industries, Inc.
2 Independence Way
Princeton, NJ 08540

	Sun Pharmaceutical Industries, Inc. 2 Independence Way Princeton, NJ 08540

	© 2025 Sun Pharmaceutical Industries, Inc. All rights reserved. PM-US-NP-0170 10/25